3.2.5 Cumbersome and Lengthy Development Procedure Discourages Biomarker Research by the Pharmaceutical Sector 18
4 Personalized Medicine Market – Personalized Therapeutics and Diagnostics 19
4.1 Personalized Therapeutics – Drug Profiles 19
4.1.1 Herceptin (trastuzumab) 19
4.1.2 Erbitux (cetuximab) 24
4.1.3 Gleevec (imatinib) 28
4.1.4 Zyprexa (olazapine) 32
4.1.5 Lipitor (atorvastatin) 35
4.1.6 Celebrex (celecoxib) 39
4.1.7 Tarceva (erlotinib) 42
4.1.8 Rituxan (rituximab) 46
4.1.9 Plavix (clopidogrel bisulfate) 49
4.1.10 Risperdal (risperidone) 51
4.1.11 Vectibix (Panitumumab) 54
4.1.12 Coumadin (Warfarin) 56
4.1.13 Iressa (Gefitinib) 57
4.1.14 Sprycel 59
4.1.15 Camptosar 61
4.2 Companion Diagnostics 62
4.2.1 Selected Companion Diagnostics Employed in Personalized Healthcare 64
4.3 Biomarkers 67
4.3.1 Biomarkers in Cancer Research 68
4.3.2 Market Size and Forecasts 69
4.3.3 Segmentation by Indication 70
5 Personalized Medicine Market: Selected Pipeline Product Profiles 80
5.1 PF-4948568 (Pfizer) 80
5.1.1 Overview 80
5.1.2 Mechanism of Action 80
5.1.3 Clinical Study Details 80
5.2 PF-02341066 + Erlotinib (Pfizer) 81
5.2.1 Overview 81
5.2.2 Mechanism of Action 81
5.2.3 Clinical study details 81
5.3 PF-299804 (Pfizer) 82
5.3.1 Overview 82
5.3.2 Mechanism of action 82
5.3.3 Clinical study details 82
5.4 CEP-701 (Cephalon Inc.) 83
5.4.1 Overview 83
5.4.2 Mechanism of action 83
5.4.3 Clinical study details 84
5.5 TBR-652 (Tobira Therapeutics, Inc) 84
5.5.1 Overview 84
5.5.2 Mechanism of action 84
5.5.3 Clinical study details 85
5.6 Brivanib (Bristol-Myers Squibb) 85
5.6.1 Overview 85
5.6.2 Mechanis
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |